+44 79 19 49 39 39 wilsonblaney@gmail.com

[09-01-2010] The U.S. Food and Drug Administration (FDA) is reminding healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections.
What’s New: Drugs RSS Feed

Share Button